{
    "relation": [
        [
            "",
            "Placebo",
            "Dapagliflozin, 10 mg"
        ],
        [
            "Description",
            "Participants with type 2 diabetes mellitus and inadequate glycemic and hypertension control while taking an oral antidiabetic agent (OAD) with or without insulin and an angiotensin-converting enzyme (ACE) inhibitor or angiotension-receptor blocker (ARB) received dapagliflozin-matching placebo daily with a morning meal.",
            "Participants with type 2 diabetes mellitus and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB received dapagliflozin, 10 mg, daily with a morning meal."
        ]
    ],
    "pageTitle": "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01137474?sect=Xi0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989301.17/warc/CC-MAIN-20150728002309-00313-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 856785500,
    "recordOffset": 856770881,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Of 2996 participants enrolled, 944 were randomized and received double-blind treatment. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details This study was originally designed with 2 additional double-blind treatment arms, dapagliflozin 2.5 and 5 mg, but randomization of new patients into these arms stopped with implementation of Protocol Amendment 8 on 1-11-11. Patients randomized to dapagliflozin 2.5 or 5 mg remained on their blinded medication until study completion. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Dapagliflozin Drug: Placebo-matching dapagliflozin Drug: Oral antidiabetic agent Drug: Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) Drug: With or without insulin Interventions:",
    "textAfterTable": "Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 5 mg, daily with a morning meal. Dapagliflozin, 10 mg Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 10 mg, daily with a morning meal. Participant Flow for 2 periods Period 1: \u00a0 Day 1 to Week 12 (Double-blind Period) \u00a0 \u00a0 Placebo \u00a0 \u00a0 Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) \u00a0 \u00a0 Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) \u00a0 \u00a0 Dapagliflozin, 10 mg \u00a0 STARTED \u00a0 \u00a0 311 \u00a0 \u00a0 166 \u00a0 \u00a0 165 \u00a0 \u00a0 302 \u00a0 Received Treatment \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}